RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000068.xml
PDF herunterladen
Semin intervent Radiol 2017; 34(01): 35-49
DOI: 10.1055/s-0036-1597762
DOI: 10.1055/s-0036-1597762
Review Article
How We Manage Pediatric Deep Venous Thrombosis
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
02. März 2017 (online)
Abstract
Over the past two decades, the incidence and recognition of venous thromboembolism (VTE) in children has significantly increased, likely as a result of improvements in the medical care of critically ill patients and increased awareness of thrombotic complications among medical providers. Current recommendations for the management of VTE in children are largely based on data from pediatric registries and observational studies, or extrapolated from adult data. The scarcity of high-quality evidence-based recommendations has resulted in marked variations in the management of pediatric VTE among providers. The purpose of this article is to summarize our institutional approach for the management of VTE in children based on available evidence, guidelines, and clinical practice considerations. Therapeutic strategies reviewed in this article include the use of conventional anticoagulants, parenteral targeted anticoagulants, new direct oral anticoagulants, thrombolysis, and mechanical approaches for the management of pediatric VTE.
-
References
- 1 Vu LT, Nobuhara KK, Lee H, Farmer DL. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg 2008; 43 (6) 1095-1099
- 2 Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 2004; 145 (4) 563-565
- 3 Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124 (4) 1001-1008
- 4 Goldenberg NA, Bernard TJ. Venous thromboembolism in children. Hematol Oncol Clin North Am 2010; 24 (1) 151-166
- 5 van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Pediatr 2001; 139 (5) 676-681
- 6 Monagle P, Adams M, Mahoney M , et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47 (6) 763-766
- 7 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96 (5, Pt 1): 939-943
- 8 Setty BA, O'Brien SH, Kerlin BA. Pediatric venous thromboembolism in the United States: a tertiary care complication of chronic diseases. Pediatr Blood Cancer 2012; 59 (2) 258-264
- 9 Prandoni P, Lensing AW, Cogo A , et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (1) 1-7
- 10 Popuri RK, Vedantham S. The role of thrombolysis in the clinical management of deep vein thrombosis. Arterioscler Thromb Vasc Biol 2011; 31 (3) 479-484
- 11 Goldenberg NA, Donadini MP, Kahn SR , et al. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica 2010; 95 (11) 1952-1959
- 12 Manco-Johnson MJ. Postthrombotic syndrome in children. Acta Haematol 2006; 115 (3-4): 207-213
- 13 Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006; 107 (1) 21-29
- 14 Chalmers E, Ganesen V, Liesner R , et al; British Committee for Standards in Haematology. Guideline on the investigation, management and prevention of venous thrombosis in children. Br J Haematol 2011; 154 (2) 196-207
- 15 Monagle P, Chan AK, Goldenberg NA , et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e737S-e801S
- 16 Monagle P, Ignjatovic V, Savoia H. Hemostasis in neonates and children: pitfalls and dilemmas. Blood Rev 2010; 24 (2) 63-68
- 17 Monagle P, Barnes C, Ignjatovic V , et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95 (2) 362-372
- 18 Lewy PR, Jao W. Nephrotic syndrome in association with renal vein thrombosis in infancy. J Pediatr 1974; 85 (3) 359-365
- 19 Van Ommen CH, Peters M. Acute pulmonary embolism in childhood. Thromb Res 2006; 118 (1) 13-25
- 20 Wang CY, Ignjatovic V, Francis P , et al. Risk factors and clinical features of acute pulmonary embolism in children from the community. Thromb Res 2016; 138: 86-90
- 21 Chan AK, Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years?. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 439-443
- 22 Goldenberg NA, Knapp-Clevenger R, Hays T, Manco-Johnson MJ. Lemierre's and Lemierre's-like syndromes in children: survival and thromboembolic outcomes. Pediatrics 2005; 116 (4) e543-e548
- 23 Fraser DG, Moody AR, Davidson IR, Martel AL, Morgan PS. Deep venous thrombosis: diagnosis by using venous enhanced subtracted peak arterial MR venography versus conventional venography. Radiology 2003; 226 (3) 812-820
- 24 Thacker PG, Lee EY. Pulmonary embolism in children. AJR Am J Roentgenol 2015; 204 (6) 1278-1288
- 25 Middeldorp S. Is thrombophilia testing useful?. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 150-155
- 26 Masuda EM, Lee RW, Okazaki IJ, Benyamini P, Kistner RL. Thrombophilia testing has limited usefulness in clinical decision-making and should be used selectively. J Vasc Surg Venous Lymphat Disord 2015; 3 (2) 228-235
- 27 Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ ; Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004; 351 (11) 1081-1088
- 28 Young G, Albisetti M, Bonduel M , et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation 2008; 118 (13) 1373-1382
- 29 Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81 (5) 684-689
- 30 Nowak-Göttl U, Junker R, Kreuz W , et al; Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97 (4) 858-862
- 31 Payne JH. Aspects of anticoagulation in children. Br J Haematol 2010; 150 (3) 259-277
- 32 Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008; 122 (3) 293-298
- 33 Murphy MS, John PR, Mayer AD, Buckels JA, Kelly DA. Heparin therapy and bone fractures. Lancet 1992; 340 8827 1098
- 34 Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74 (1) 415-425
- 35 Young G. New anticoagulants in children: a review of recent studies and a look to the future. Thromb Res 2011; 127 (2) 70-74
- 36 Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108 (4, Suppl): 258S-275S
- 37 Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics 2009; 123 (3) e510-e518
- 38 Andrew M, Marzinotto V, Massicotte P , et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35 (1) 78-83
- 39 Sutor AH, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost 1997; 23 (3) 303-319
- 40 McDonald MM, Jacobson LJ, Hay Jr WW, Hathaway WE. Heparin clearance in the newborn. Pediatr Res 1981; 15 (7) 1015-1018
- 41 Schechter T, Finkelstein Y, Ali M , et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost 2012; 10 (3) 368-374
- 42 Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012; 32 (6) 546-558
- 43 Warkentin TE, Levine MN, Hirsh J , et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20) 1330-1335
- 44 Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 2004; 91 (4) 719-724
- 45 Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003; 39 (4) 289-292
- 46 Law C, Raffini L. A guide to the use of anticoagulant drugs in children. Paediatr Drugs 2015; 17 (2) 105-114
- 47 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79 (1) 1-17
- 48 Goldenberg NA, Abshire T, Blatchford PJ , et al; Kids-DOTT Trial Investigators. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings. J Thromb Haemost 2015; 13 (9) 1597-1605
- 49 Bauman ME, Belletrutti MJ, Bajzar L , et al. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels. Thromb Haemost 2009; 101 (1) 86-92
- 50 O'Brien SH, Lee H, Ritchey AK. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. J Thromb Haemost 2007; 5 (9) 1985-1987
- 51 Yee DL, O'Brien SH, Young G. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet 2013; 52 (11) 967-980
- 52 Streif W, Andrew M, Marzinotto V , et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94 (9) 3007-3014
- 53 Nowak-Göttl U, Dietrich K, Schaffranek D , et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 2010; 116 (26) 6101-6105
- 54 Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12 (Suppl F): 27F-32
- 55 Rayapudi S, Torres Jr A, Deshpande GG , et al. Bivalirudin for anticoagulation in children. Pediatr Blood Cancer 2008; 51 (6) 798-801
- 56 Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007; 5 (8) 1654-1659
- 57 Forbes TJ, Hijazi Z, Young G. Bivalirudin as a procedural anticoagulant in the pediatric population undergoing intravascular procedures for congenital heart disease. Catheter Cardiovasc Interv 2011; 77 (5) 671-679
- 58 Young G, Boshkov LK, Sullivan JE , et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer 2011; 56 (7) 1103-1109
- 59 O'Brien SH, Yee DL, Lira J, Goldenberg NA, Young G. UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis. J Thromb Haemost 2015; 13 (9) 1615-1622
- 60 Madabushi R, Cox DS, Hossain M , et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol 2011; 51 (1) 19-28
- 61 Ko RH, Michieli C, Lira JL, Young G. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res 2014; 134 (3) 643-647
- 62 Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer 2011; 57 (6) 1049-1054
- 63 von Vajna E, Alam R, So TY. Current clinical trials on the use of direct oral anticoagulants in the pediatric population. Cardiol Ther 2016; 5 (1) 19-41
- 64 Lyle CA, Sidonio RF, Goldenberg NA. New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants. Curr Opin Pediatr 2015; 27 (1) 18-25
- 65 Gillespie MA, Lyle CA, Goldenberg NA. Updates in pediatric venous thromboembolism. Curr Opin Hematol 2015; 22 (5) 413-419
- 66 Martinelli I, Bucciarelli P, Artoni A , et al. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. Pediatrics 2013; 132 (5) e1435-e1439
- 67 Beyer-Westendorf J, Gehrisch S. Pharmacokinetics of rivaroxaban in adolescents. Hamostaseologie 2014; 34 (1) 85-87
- 68 Dietrich K, Stang L, van Ryn J, Mitchell LG. Assessing the anticoagulant effect of dabigatran in children: an in vitro study. Thromb Res 2015; 135 (4) 630-635
- 69 Boehringer Ingelheim. Safety and tolerability of dabigatran etexilate in adolescents. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. . NLM Identifier: NCT00844415
- 70 Boehringer Ingelheim. Tolerability, PK/PD and safety of dabigatran etexilate oral liquid formulation in children\1year of age. In: ClinicalTrials.gov [internet]. Bethesda, MD: National Library of Medicine (US); 2000. . NLM identifier: NCT02223260
- 71 Boehringer Ingelheim. Pharmacokinetics, safety and tolerability of dabigatran etexilate solution in children 1 to \2 years of age. . In: ClinicalTrials.gov [internet]. Bethesda, MD: National Library of Medicine (US); 2000. . NLM identifier: NCT01773174
- 72 Boehringer Ingelheim. Safety and tolerability of dabigatran etexilate solution in children 1 to \12 years of age. . In: ClinicalTrials.gov [internet]. Bethesda, MD: National Library of Medicine (US); 2000. . NLM identifier: NCT01083732
- 73 Boehringer Ingelheim. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). In: ClinicalTrials.gov [internet]. Bethesda, MD: National Library of Medicine (US); 2000. . NLM identifier: NCT01895777
- 74 Boehringer Ingelheim. Safety of dabigatran etexilate in blood clot prevention in children. In: ClinicalTrials.gov [internet]. Bethesda, MD: National Library of Medicine (US); 2000. . NLM identifier: NCT02197416
- 75 Bayer. Rivaroxaban pharmacokinetics/ pharmacodynamics (PK/PD) study in pediatric subjects. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. ;NLM Identifier: NCT01145859. Accessed July 9, 2016
- 76 EINSTEIN Junior Phase II. Oral rivaroxaban in young children with venous thrombosis (EINSTEIN Jr). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. ; NLM Identifier: NCT02309411. Accessed July 9, 2016
- 77 Bayer. Oral rivaroxaban in children with venous thrombosis (EINSTEIN Junior). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. ; NLM Identifier: 01684423. Accessed July 9, 2016
- 78 EINSTEIN Junior Phase III. Oral rivaroxaban in children with venous thrombosis (EINSTEIN Jr). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. . NLM Identifier: NCT02234843. Accessed July 9, 2016
- 79 Pollack Jr CV, Reilly PA, Eikelboom J , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (6) 511-520
- 80 Ansell JE. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis 2016; 41 (2) 248-252
- 81 Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M ; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160 (1) 35-46
- 82 Jaff MR, McMurtry MS, Archer SL , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123 (16) 1788-1830
- 83 Vedantham S, Sista AK, Klein SJ , et al; Society of Interventional Radiology and Cardiovascular and Interventional Radiological Society of Europe Standards of Practice Committees. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol 2014; 25 (9) 1317-1325
- 84 Vedantham S, Piazza G, Sista AK, Goldenberg NA. Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (1) 68-80
- 85 Raffini L. Thrombolysis for intravascular thrombosis in neonates and children. Curr Opin Pediatr 2009; 21 (1) 9-14
- 86 Albisetti M. Thrombolytic therapy in children. Thromb Res 2006; 118 (1) 95-105
- 87 Manco-Johnson MJ, Nuss R, Hays T, Krupski W, Drose J, Manco-Johnson ML. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000; 136 (4) 446-453
- 88 Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110 (1) 45-53
- 89 Vedantham S, Vesely TM, Sicard GA , et al. Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis. J Vasc Interv Radiol 2004; 15 (6) 565-574
- 90 Bush RL, Lin PH, Bates JT, Mureebe L, Zhou W, Lumsden AB. Pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis: safety and feasibility study. J Vasc Surg 2004; 40 (5) 965-970
- 91 Goldenberg NA, Branchford B, Wang M, Ray Jr C, Durham JD, Manco-Johnson MJ. Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism. J Vasc Interv Radiol 2011; 22 (2) 121-132
- 92 Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984; 76 (3) 393-397
- 93 Baadh AS, Zikria JF, Rivoli S, Graham RE, Javit D, Ansell JE. Indications for inferior vena cava filter placement: do physicians comply with guidelines?. J Vasc Interv Radiol 2012; 23 (8) 989-995
- 94 Nazzal M, Chan E, Nazzal M , et al. Complications related to inferior vena cava filters: a single-center experience. Ann Vasc Surg 2010; 24 (4) 480-486
- 95 Blevins EM, Glanz K, Huang YS, Raffini L, Shinohara RT, Witmer C. A multicenter cohort study of inferior vena cava filter use in children. Pediatr Blood Cancer 2015; 62 (12) 2089-2093
- 96 Ahmad I, Yeddula K, Wicky S, Kalva SP. Clinical sequelae of thrombus in an inferior vena cava filter. Cardiovasc Intervent Radiol 2010; 33 (2) 285-289
- 97 Musani MH, Matta F, Yaekoub AY, Liang J, Hull RD, Stein PD. Venous compression for prevention of postthrombotic syndrome: a meta-analysis. Am J Med 2010; 123 (8) 735-740
- 98 Labropoulos N, Gasparis AP, Caprini JA, Partsch H. Compression stockings to prevent post-thrombotic syndrome. Lancet 2014; 384 9938 129-130
- 99 Illig KA, Doyle AJ. A comprehensive review of Paget-Schroetter syndrome. J Vasc Surg 2010; 51 (6) 1538-1547
- 100 Gharagozloo F, Meyer M, Tempesta B, Strother E, Margolis M, Neville R. Proposed pathogenesis of Paget-Schroetter disease: impingement of the subclavian vein by a congenitally malformed bony tubercle on the first rib. J Clin Pathol 2012; 65 (3) 262-266
- 101 Arthur LG, Teich S, Hogan M, Caniano DA, Smead W. Pediatric thoracic outlet syndrome: a disorder with serious vascular complications. J Pediatr Surg 2008; 43 (6) 1089-1094
- 102 Maru S, Dosluoglu H, Dryjski M, Cherr G, Curl GR, Harris LM. Thoracic outlet syndrome in children and young adults. Eur J Vasc Endovasc Surg 2009; 38 (5) 560-564
- 103 Horattas MC, Wright DJ, Fenton AH , et al. Changing concepts of deep venous thrombosis of the upper extremity--report of a series and review of the literature. Surgery 1988; 104 (3) 561-567
- 104 Urschel Jr HC, Razzuk MA. Paget-Schroetter syndrome: what is the best management?. Ann Thorac Surg 2000; 69 (6) 1663-1668 , discussion 1668–1669
- 105 Thompson JF, Winterborn RJ, Bays S, White H, Kinsella DC, Watkinson AF. Venous thoracic outlet compression and the Paget-Schroetter syndrome: a review and recommendations for management. Cardiovasc Intervent Radiol 2011; 34 (5) 903-910
- 106 Taylor JM, Telford RJ, Kinsella DC, Watkinson AF, Thompson JF. Long-term clinical and functional outcome following treatment for Paget-Schroetter syndrome. Br J Surg 2013; 100 (11) 1459-1464
- 107 Avila ML, Duan L, Cipolla A , et al. Postthrombotic syndrome following upper extremity deep vein thrombosis in children. Blood 2014; 124 (7) 1166-1173
- 108 Vercellio G, Baraldini V, Gatti C, Coletti M, Cipolat L. Thoracic outlet syndrome in paediatrics: clinical presentation, surgical treatment, and outcome in a series of eight children. J Pediatr Surg 2003; 38 (1) 58-61
- 109 Trenor III CC, Fisher JG, Khan FA , et al. Paget-Schroetter syndrome in 21 children: outcomes after multidisciplinary care. J Pediatr 2015; 166 (6) 1493-7.e1
- 110 Brandão LR, Williams S, Kahr WHA, Ryan C, Temple M, Chan AK. Exercise-induced deep vein thrombosis of the upper extremity. 2. A case series in children. Acta Haematol 2006; 115 (3-4): 221-229
- 111 Rigberg DA, Gelabert H. The management of thoracic outlet syndrome in teenaged patients. Ann Vasc Surg 2009; 23 (3) 335-340
- 112 Lee JT, Karwowski JK, Harris EJ, Haukoos JS, Olcott IV C. Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome. J Vasc Surg 2006; 43 (6) 1236-1243
- 113 Raffini L, Raybagkar D, Cahill AM, Kaye R, Blumenstein M, Manno C. May-Thurner syndrome (iliac vein compression) and thrombosis in adolescents. Pediatr Blood Cancer 2006; 47 (6) 834-838
- 114 O'Sullivan GJ, Semba CP, Bittner CA , et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol 2000; 11 (7) 823-836
- 115 Knipp BS, Ferguson E, Williams DM , et al. Factors associated with outcome after interventional treatment of symptomatic iliac vein compression syndrome. J Vasc Surg 2007; 46 (4) 743-749
- 116 Hurst DR, Forauer AR, Bloom JR, Greenfield LJ, Wakefield TW, Williams DM. Diagnosis and endovascular treatment of iliocaval compression syndrome. J Vasc Surg 2001; 34 (1) 106-113
- 117 Shebel ND, Whalen CC. Diagnosis and management of iliac vein compression syndrome. J Vasc Nurs 2005; 23 (1) 10-17 , quiz 18–19
- 118 Birn J, Vedantham S. May-Thurner syndrome and other obstructive iliac vein lesions: meaning, myth, and mystery. Vasc Med 2015; 20 (1) 74-83
- 119 Liu Z, Gao N, Shen L , et al. Endovascular treatment for symptomatic iliac vein compression syndrome: a prospective consecutive series of 48 patients. Ann Vasc Surg 2014; 28 (3) 695-704
- 120 Brazeau NF, Harvey HB, Pinto EG, Deipolyi A, Hesketh RL, Oklu R. May-Thurner syndrome: diagnosis and management. Vasa 2013; 42 (2) 96-105
- 121 Sharifi M, Mehdipour M, Bay C, Smith G, Sharifi J. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. Catheter Cardiovasc Interv 2010; 76 (3) 316-325
- 122 Enden T, Haig Y, Kløw NE , et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379 9810 31-38
- 123 Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002; 24 (3) 209-214
- 124 Oliver M, Kurnik K, Hoffman F. Ultrasound assisted endovascular thrombolysis in adolescents: 2. Case Rep Pediatr 2016; 138 (1) 2016-2022
- 125 Moudgill N, Hager E, Gonsalves C, Larson R, Lombardi J, DiMuzio P. May-Thurner syndrome: case report and review of the literature involving modern endovascular therapy. Vascular 2009; 17 (6) 330-335